8-(pyridin-4-yl)-2,8-diazaspiro[4.5]decane | 336191-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 8-(pyridin-4-yl)-2,8-diazaspiro[4.5]decane
• 英文别名: 2,8-diaza-8-(4-pyridyl)spiro[4.5]decane；8-(4-Pyridyl)-2,8-diazaspiro[4.5]decane；8-pyridin-4-yl-2,8-diazaspiro[4.5]decane
• CAS: 336191-19-6
• 化学式: C₁₃H₁₉N₃
• 分子量: 217.314
• InChiKey: PNURJQDYWZUTNN-UHFFFAOYSA-N

物化性质

• 沸点：
  376.1±32.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-(pyridin-4-yl)-2,8-diazaspiro[4.5]decane 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-(2-oxo-4-((8-(pyridin-4-yl)-2,8-diazaspiro[4.5]dec-2-yl)carbonyl)-piperazino)propanoic acid
  参考文献：
  名称：

  Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

  摘要：

  The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00095-1
• 作为产物：
  描述：

  8-苄基-2,8-二氮杂-螺[4,5]葵烷 在 palladium dihydroxide sodium hydroxide 、 tris(dibenzylideneacetone)dipalladium (0) 、 氢气 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 三氟乙酸 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 95.0 ℃ 、689.47 kPa 条件下， 生成 8-(pyridin-4-yl)-2,8-diazaspiro[4.5]decane
  参考文献：
  名称：

  Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

  摘要：

  The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00095-1

文献信息

• Substituted Indole Compounds
  申请人：Schunk Stefan

  公开号：US20100222324A1

  公开（公告）日：2010-09-02

  Substituted indole compounds corresponding to the formula I: In which R 8 , R 9a , R 9b , R 10 , R 11 , R 200 , R 210 , A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).

  将与下式I对应的吲哚化合物替代： 其中R8、R9a、R9b、R10、R11、R200、R210、A、D、T、q、s和t具有定义的含义，其制备方法，含有这种化合物的药物组合物以及用于治疗或抑制至少部分由Bradykinin 1受体（B1R）介导的疼痛和其他病症的替代吲哚化合物的用途。
• Substituted Disulfonamide Compounds
  申请人：REICH Melanie

  公开号：US20100152158A1

  公开（公告）日：2010-06-17

  Substituted disulfonamide compounds corresponding to formula I: In which R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 8 , R 9a , R 9b , R 10 , R 11 , a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin receptor 1 (BR1).

  将对应于公式I的取代二磺酰胺化合物： 其中R 1 ，R 2 ，R 3 ，R 4a ，R 4b ，R 5a ，R 5b ，R 8 ，R 9a ，R 9b ，R 10 ，R 11 ，a，b，s，t和A具有定义的含义，包含一种或多种此类化合物的药物组合物，制备这种化合物的方法，以及使用这种化合物治疗或抑制由激肽酶受体1（BR1）介导的疼痛和/或其他病症的方法。
• Substituted Spiro-amide Compounds
  申请人：Schunk Stefan

  公开号：US20100249095A1

  公开（公告）日：2010-09-30

  Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

  将与式I相对应的螺环酰胺化合物替代为R5至R8、D、X、Y和Z具有定义含义的过程，用于制备这种螺环酰胺化合物，含有这种化合物的药物组合物，以及使用这种螺环酰胺化合物治疗和/或抑制至少部分由激肽酶1受体介导的疾病或疾病状态的方法。
• Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
  申请人：——

  公开号：US20030055244A1

  公开（公告）日：2003-03-20

  Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis

  本发明涉及某些含有取代或未取代吡啶基的螺环化合物，其取代有碱性和酸性功能，可用于抑制血小板聚集，抑制纤维蛋白原与血小板的结合，并预防或治疗血栓形成。
• Substituted Pyrimidine and Triazine Compounds
  申请人：Schunk Stefan

  公开号：US20100173889A1

  公开（公告）日：2010-07-08

  Substituted pyrimidine and triazine compounds corresponding to formula I wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 7 , R 8 , R 9a , R 9b , R 10 , R 11 , A, a, b, s, t, V, W 1 , W 2 and W 3 have defined meanings, pharmaceutical compositions comprising such compounds, a process for preparing such compounds, and the use of such compounds and compositions to treat or inhibit pain and/or other disorders or disease states.

  将对应于公式I的嘧啶和三嗪化合物替代为R1、R2、R3、R4a、R4b、R5a、R5b、R7、R8、R9a、R9b、R10、R11、A、a、b、s、t、V、W1、W2和W3具有定义意义，包括这种化合物的药物组合物、制备这种化合物的过程，以及使用这种化合物和组合物来治疗或抑制疼痛和/或其他疾病状态的专利。